Top press release

Social Link

Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price

  • Grand News Network
  • November 8, 2023

The FDA has approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. 

The active ingredient in the drug, tirzepatide, has already been approved for Type 2 diabetes under the name Mounjaro since May 2022.

Mounjaro (Type 2 diabetes injection) Q3 sales reached $1.41 billion compared to $187.3 million ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner

Technical analysis widget

Economic calendar widget

Market overview